CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...
Phase 1, Phase 2
New Haven, Connecticut, United States and 8 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
New Britain, Connecticut, United States and 319 other locations
To assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)* To characterize the pharmacokinetic (PK) properties of RGLS...
Phase 1
New Haven, Connecticut, United States and 27 other locations
Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...
Phase 3
New Haven, Connecticut, United States and 29 other locations
compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effec...
Phase 2
Waterbury, Connecticut, United States and 116 other locations
CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney...
Phase 2
Stamford, Connecticut, United States and 48 other locations
Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial ...
Phase 3
New Haven, Connecticut, United States and 338 other locations
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys...
Phase 2
New Haven, Connecticut, United States and 167 other locations
receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...
Phase 2
Waterbury, Massachusetts, United States of America and 188 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
New Haven, Connecticut, United States and 297 other locations
Clinical trials
Research sites
Resources
Legal